Scouts
What should a scout ask about eligible carry on a healthcare software startup?
a healthcare software startup: Eligible carry requires an agreement, a defined base, and the events that can create distributable amounts.
Eligible carry requires an agreement, a defined base, and the events that can create distributable amounts. A headline percentage does not specify deductions, timing, follow-ons, vesting, or termination treatment. A sourced investment can produce no carry.
Start with the decision
Map the actual agreement's conditions and use fictional arithmetic only to explain the mechanism. Include a zero-distribution case. Ask qualified advisers about legal and tax terms and avoid treating future carry as expected income.
The illustrative scenario
This is an educational workbook. The company or fund and all numerical inputs below are fictional. They are not ADIN results, customer claims, market benchmarks, or a forecast.
The fictional team is piloting an administrative scheduling product with a provider group. Staff use it in a narrow workflow, while procurement and data review determine whether a broader rollout is possible.
A clinic's enthusiasm does not resolve data handling, workflow ownership, or applicable regulatory questions. This example does not assume a particular legal classification or approval.
Carry arithmetic after an explicitly assumed base
For this fictional example only, assume the applicable agreement defines $35,000.00 as distributable net carry and allocates half of that amount to the scout. Multiplication gives $17,500.00. The difficult question precedes the multiplication: whether the deal qualifies and whether the defined distributable base ever exists.
A paper valuation, a completed introduction, or the fund's first investment does not establish that payment is due. Eligibility, attribution, deductions, follow-on treatment, vesting, and payment timing need the actual agreement. The zero-base row is as important as the positive row because an investment may never create distributable carry.
A clinic's enthusiasm does not resolve data handling, workflow ownership, or applicable regulatory questions. This example does not assume a particular legal classification or approval. Keep company evaluation separate from compensation expectations. ADIN's GPs make the final investment decision, and the public scout page should be read together with the applicable agreement. This example is an explanation of arithmetic and questions, not a projection of income or a legal interpretation.
| Item | Illustration |
|---|---|
| Invented distributable net carry base | $35,000.00 |
| Assumed share for this exercise | 50% |
| Multiplication under those assumptions | $17,500.00 |
| Share if eligible net carry is zero | $0.00 |
Use this worksheet
Answer the questions with a source, date, owner, and next action. Mark an unknown as unknown. Use public or permissioned information and involve a qualified specialist when a question requires expertise beyond the team’s competence.
- What amount is the percentage applied to?
- What deductions come first?
- Which investment qualifies?
- When can payment occur?
- What survives leaving the program?
Questions specific to this scenario
- Which workflow is actually in scope?
- Who approves data access?
- What specialist review is needed?
Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet.
A concrete next test
Ask the authorized workflow owner to map a narrow administrative use case without disclosing patient information. Identify the data-access and procurement approvals needed for the next step. Keep operational adoption evidence separate from claims about clinical benefit or regulatory status.
Interpret the result
A multiplication example does not predict an exit or describe every waterfall. ADIN's public program copy and the applicable agreement should be read together, with GPs retaining the final investment decision.
Compare the administrative workflow and rollout dependencies with the current process. Do not treat an operational pilot as clinical efficacy evidence.
Sources and method
These primary resources provide background for the concepts. The fictional scenario, calculations, and worksheet are ADIN educational examples; the sources do not report or validate those invented results. Reviewed October 11, 2026.